Clare Spooner

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi et al. · Blood · 2021 · 75 citations

Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study

Donah Zachariah, D. Stevens, G. Sidorowicz et al. · International Journal of Cardiology · 2017 · 24 citations

Quality Of Life, Life Assessment, Heart Failure +15

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson et al. · Blood · 2024 · 23 citations · Full text

Immunology, Pathology, Cell Replacement Therapy +22

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, Zhen‐Huan Hu, Tanya Siddiqi et al. · Blood · 2022 · 22 citations

Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1

Sachin Vadgama, Jess Mann, Zahid Bashir et al. · Value in Health · 2022 · 14 citations · Full text